Compile Data Set for Download or QSAR
maximum 50k data
Found 364 with Last Name = 'walker' and Initial = 'mm'
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morph...)
Affinity DataIC50:  0.00200nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morph...)
Affinity DataIC50:  0.00200nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50:  0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50:  0.00900nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50:  0.00900nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morph...)
Affinity DataIC50:  0.236nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morph...)
Affinity DataIC50:  0.236nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50:  0.356nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50:  0.356nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50:  0.356nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50377170(CHEMBL256570 | US11254667, Compound I-2 | US115422...)
Affinity DataIC50: <0.5nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetInterleukin-1 receptor-associated kinase 4(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetDimer of Receptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538658(NCGC 00249373 | US11254667, Compound I-17 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Lck(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetProto-oncogene tyrosine-protein kinase receptor Ret(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase Blk(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50: <0.508nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538658(NCGC 00249373 | US11254667, Compound I-17 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538619(NCGC 00371479 | US11254667, Compound I-22 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538621(NCGC 00371481 | US11254667, Compound I-24 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538658(NCGC 00249373 | US11254667, Compound I-17 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetReceptor-type tyrosine-protein kinase FLT3 [D835Y](Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM538618(NCGC 00262327 | US11254667, Compound I-20 | US1154...)
Affinity DataIC50: <0.508nMAssay Description:Table 8-10: Compounds were tested in 10-dose IC50 mode with 3-fold serial dilution starting at 10 uM, and are relative to DMSO, the negative control....More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM139540(US10189849, staurosporine | US10307427, Staurospor...)
Affinity DataIC50:  0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morph...)
Affinity DataIC50:  0.623nMAssay Description:Table 7 For most assays, kinase-tagged T7 phage strains were prepared in an E. coli host derived from the BL21 strain. E. coli were grown to log-phas...More data for this Ligand-Target Pair
In DepthDetails US Patent
TargetCyclin-H/Cyclin-dependent kinase 7(Homo sapiens (Human))
Children'S Hospital Medical Center

US Patent
LigandPNGBDBM50300690(1-(5-Tert-Butyl-1,2-Oxazol-3-Yl)-3-(4-{7-[2-(Morph...)
Affinity DataIC50:  0.623nMAssay Description:Table 3 and 4: The HotSpot kinase profiling and screening assays were carried out using the method of Anastassiadis et al., Nat. Biotechnol. (2011) V...More data for this Ligand-Target Pair
In DepthDetails US Patent
Displayed 1 to 50 (of 364 total ) | Next | Last >>
Jump to: